Member Info for Lionel1

Interesting read : Genedrive is clearly the winner out of all.

In the probabilistic analysis, we observed that when the long-term stroke rate is increased, there is less uncertainty over the cost-effectiveness of the tests. In the PSA which uses the rate from Amarenco et al. (2018) in the Markov model (Scenario BH1), we see an increase in the proportion or PSA iterations which are cost-errective. Using a tzu,ooo per vALY willingness to pay threshola, 80% of Genedrive Iterations were cost-effective against no test, 84% of Genomadix iterations were cost-effective against no test, and 83% of lab tests were cost-effective against

no test. In the crac, due to the strong correlation between ine terations where the tests were cost-errective, when testing was cost-errective

Genedrive tended to dominate across WTP thresholds analvsed

NICE update : 6 hrs ago

https://www.nice.org.uk/guidance/GID-DG10054/documents/d-a-r-addendum-4

@slacker , The market thinks otherwise.. There is a positive sentiment overall .. I am sure it is a safe bet at this levels …

Bought another 255528 (16,583£) Thank you.

@David , you are spamming here :-)

@guy one thing that agree with you , nobody has a clue :-)

@papaya , did you sell out ?? You changed your tune :-)

Https://www.voxmarkets.co.uk/rns/announcement/3850c15c-6c70-42ed-867c-0f08c3fd37bf/

Sheffield and Derbyshire likely next …

Https://youtu.be/83YHujUl_e0?si=w2uwipN3J7F-9JLa

Thank you Eureka , GDR is one of the most popular stock for good and bad reasons , one thing is clear that many people are still watching from side lines.. whiff of good news and this will fly ..

Roger , Do you think I have invested here without doing due diligence ?? I know what I am in for and I have a clear picture what’s going on , don’t you worry about me .. i am not a trader so I am not really worried about day movements … I am sorry for the investors who bought above 20 p .. I would say it takes time but not impossible.. the sentiment is very low at the moment .. I don’t understand few always hang around here like an addict :-) ..

Roger , you are a joke :-) or under medication .. There is a pattern in your writings and u are exposed many times but you still come here to put your nonsense or verbal diarrhoea :-) .. if you are not invested then just f**ff and leave this space for poor investors … one simple thing if u have any common sense .. NHS has 2 legs ( 2 important tests ) in GDR with govt grant and all .. u saying Saudi will buy for 1 mil ..:-) . What kind of fool u are .. I would say Grade 1 …

They are recruiting more staff :-)

Once I agree with you , something is afoot … suspicious

The finance deal with Riverfort is killing the company , disappointed but not lost the hope ..

I have a feeling we will hear a significant news about CYP2C19 kit in next couple of weeks ..

Roger don’t worry nobody missed you .. :-) .. James Cheek played key role commercialising this product .. the people moaning here clearly no knowledge how the Pharma/medical companies work :-) ..

Thanks Jimi and Stephen , This is significant for GDR if they managed to get this test out ..

https://hospitalhealthcare.com/clinical/cardiovascular/using-genetic-testing-to-improve-medicines-use-after-myocardial-infarction/

Quote from the Article :

Implementing genetic testing

Genetic testing may soon be available within the NHS to determine if stroke patients would benefit from clopidogrel.19 This means that some patients might already know their CYP2C19 genotype when they present with a secondary ischaemic event.

https://www.rcplondon.ac.uk/file/48359/download

Has anyone seen any other hospital trust trialing this out ??

https://shtg.scot/media/2407/20231010-clopidogrel-genotype-testing-scope-v10.pdf

https://shtg.scot/our-advice/clopidogrel-genotype-testing-after-ischaemic-stroke-or-transient-ischaemic-attack-tia/